NICE turns down hyperkalaemia therapies
Preliminary guidelines released by the National Institute for Health and Care Excellence do not recommend NHS funding for hyperkalaemia treatments Lokelma and Veltassa.
Read More
Tag: Vifor Pharma
Pharma firms fall foul of ABPI Code
Vifor Pharma, Celgene, Takeda and Pierre Fabre have been named in advertisements for breaching the Association of the British Pharmaceutical Industry’s (ABPI) Code of Practice thus bringing discredit upon and reducing confidence in the sector.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
